Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX).

Full DD Report for ACRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: ACRX)

FDA OKs first non-opioid treatment for opioid withdrawal
The FDA approves privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the management of opioid withdrawal symptoms in adults who abruptly discontinue opioids. More news on: Endo International plc, Allergan plc, Johnson & Johnson, Healthcare stocks news, Read ...
Source: SeekingAlpha
Date: May, 16 2018 16:44
After Hours Gainers / Losers (05/15/2018)
Top gainers:   BOOT   +8.4% .  ACRX +3.6% . EBIO   +3.4% . PETQ +3.1% . SUPV   +2.8% . More news on: Boot Barn Holdings, AcelRx Pharmaceuticals, Inc., Eleven Biotherapeutics, Inc., Stocks on the move, , News on ETFs, Read more ...
Source: SeekingAlpha
Date: May, 15 2018 17:35
Blog Exposure - AcelRx Pharma Resubmitted New Drug Application for DSUVIA with FDA
Stock Monitor: ABIOMED Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 11, 2018 / If you want access to our free research report on AcelRx Pharma, Inc. (NASDAQ: ACRX ), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?sy...
Source: ACCESSWIRE IA
Date: May, 11 2018 07:10
Your Daily Pharma Scoop: AcelRx Resubmits, MannKind Finds New Realms, VTVT Up On Mixed Data
Analysis focus: ACRX If you recall your AcelRx (NASDAQ: ACRX ), it got a CRL for DSUVIA lasy year citing safety concerns and drug administration issues. The exact things the FDA said, as reported by the company, were: “The two primary recommendations within the CRL are: first, while...
Source: SeekingAlpha
Date: May, 10 2018 10:00
AcelRx Pharmaceuticals' (ACRX) CEO Vince Angotti on Q1 2018 Results - Earnings Call Transcript
AcelRx Pharmaceuticals, Inc. (ACRX) Q1 2018 Earnings Conference Call May 9, 2018 04:30 PM ET Executives Vince Angotti - CEO Pamela Palmer - Co-Founder and Chief Medical Officer Raffi Asadorian - CFO John Saia - General Counsel Analysts Randall Stanicky - RBC Capital Marke...
Source: SeekingAlpha
Date: May, 09 2018 19:27
AcelRx Pharmaceuticals beats by $0.01, misses on revenue
AcelRx Pharmaceuticals (NASDAQ: ACRX ): Q1 EPS of -$0.23 beats by $0.01 . Revenue of $0.34M (-89.1% Y/Y) misses by $0.81M . Shares +2% . Press Release More news on: AcelRx Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 09 2018 16:09
AcelRx Pharmaceuticals Reports First Quarter 2018 Financial Results
REDWOOD CITY, Calif. , May 9, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today reported its first quarter 2018 financial results. "The...
Source: PR Newswire
Date: May, 09 2018 16:05
AcelRx refiles U.S. marketing application for Dsuvia, action date Q4; shares up 10% premarket
AcelRx Pharmaceuticals (NASDAQ: ACRX ) is up  10%  premarket on light volume on the heels of its announcement that it has resubmitted its marketing application to the FDA seeking approval for pain med DSUVIA (sufentanil sublingual tablet, 30 mcg). More news on: AcelRx Pharmaceu...
Source: SeekingAlpha
Date: May, 09 2018 08:43
Stocks Under Scanner in the Medical Equipment Space - Accuray and Two more Stock Research Monitor: ACRX, and CHFS
LONDON, UK / ACCESSWIRE / May 9, 2018 / If you want a free Stock Review on ARAY sign up now at www.wallstequities.com/registration . On Tuesday, May 08, 2018, the NASDAQ Composite ended the trading session at 7,266.90, up 0.02%; the Dow Jones Industrial Average edged 0.01% higher, to finish...
Source: ACCESSWIRE IA
Date: May, 09 2018 07:45
AcelRx resubmits New Drug Application for DSUVIA(TM)
REDWOOD CITY, Calif. , May 9, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced the resubmission of the New Drug Appli...
Source: PR Newswire
Date: May, 09 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-133.103.0253.103.00182,554
2018-08-093.153.0753.153.05567,808
2018-08-082.903.003.152.901,037,923
2018-08-072.902.902.952.80646,671
2018-08-062.802.7252.8252.65544,185

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1328,13657,84548.6403Short
2018-08-1055,908121,66945.9509Short
2018-08-09107,849233,79246.1303Short
2018-08-08152,156605,73925.1191Cover
2018-08-07167,134420,92039.7068Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ACRX.


About AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)

Logo for AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $127,247,885 - 05/11/2018
  • Issue and Outstanding: 50,899,154 - 02/26/2018

 


Recent Filings from (NASDAQ: ACRX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 23 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 23 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 23 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018

 

 


Daily Technical Chart for (NASDAQ: ACRX)

Daily Technical Chart for (NASDAQ: ACRX)


Stay tuned for daily updates and more on (NASDAQ: ACRX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ACRX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ACRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ACRX and does not buy, sell, or trade any shares of ACRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/